IN8bio (INAB) stock

Worth $9.7MShares as of Nov 2

$0.90

-4.27%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score INAB. It is too small, priced too low, and too thinly traded for a fair Quality Score.

Healthcare · Biotech

Cash$14.2M, about 3 quarters at the last year's spendingOn Sep 30 · the company says “into the first half of 2027”

Follow INAB's trial news. Pro members can get an alert when IN8bio files news, and see its trials, share raises, and its CEO's filings.

Get an alert when INAB files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$14.2M, about 3 quarters at the last year's spendingOn Sep 30 · the company says “into the first half of 2027”

What's next for INAB, and how long its cash lasts

Its trials

A trial underway: Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed GlioblastomaPhase 1/2 · Active · 4 people · main data estimated Dec 2026 · NCT05664243

For Pro members: 41 filings.

Cash runway Sep 30 balance sheet

About 3 quarters

$14.2M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into the first half of 2027” (8-K, Mar 12).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Nov 7, 2025)
At-the-market share sales program (424B5, filed Jun 1, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when William Ho buys or sells

For Pro members: every trade, and William Ho’s 13 filings and quotes.

Get an alert when INAB files news on its trialA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

INAB's latest filings

Quarterly report10-Q, filed Nov 5
IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights8-K, filed Nov 5
Prospectus for a sale of securities424B5, filed Jun 1

17 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why INAB isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. INAB is worth about $9.7M, trades at $0.90, and about 40,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.